Cancer  ||| S:0 E:7 ||| NN
gene  ||| S:7 E:12 ||| NN
therapy  ||| S:12 E:20 ||| NN
with  ||| S:20 E:25 ||| IN
oncolytic  ||| S:25 E:35 ||| JJ
adenoviruses  ||| S:35 E:48 ||| JJ
Metastatic  ||| S:48 E:59 ||| JJ
cancer  ||| S:59 E:66 ||| NN
remains  ||| S:66 E:74 ||| VBZ
difficult  ||| S:74 E:84 ||| JJ
to  ||| S:84 E:87 ||| TO
treat  ||| S:87 E:93 ||| VB
effectively  ||| S:93 E:105 ||| RB
and  ||| S:105 E:109 ||| CC
treatments  ||| S:109 E:120 ||| NNS
are  ||| S:120 E:124 ||| VBP
in  ||| S:124 E:127 ||| IN
most  ||| S:127 E:132 ||| JJS
cases  ||| S:132 E:138 ||| NNS
not  ||| S:138 E:142 ||| RB
curative  ||| S:142 E:151 ||| VBN
despite  ||| S:151 E:159 ||| IN
significant  ||| S:159 E:171 ||| JJ
side  ||| S:171 E:176 ||| NN
effects ||| S:176 E:183 ||| NNS
.  ||| S:183 E:185 ||| .
Novel ||| S:185 E:190 ||| NN
,  ||| S:190 E:192 ||| ,
targeted  ||| S:192 E:201 ||| VBN
approaches  ||| S:201 E:212 ||| NNS
such  ||| S:212 E:217 ||| JJ
as  ||| S:217 E:220 ||| IN
gene  ||| S:220 E:225 ||| NN
therapy  ||| S:225 E:233 ||| NN
hold  ||| S:233 E:238 ||| NN
promise  ||| S:238 E:246 ||| NN
for  ||| S:246 E:250 ||| IN
the  ||| S:250 E:254 ||| DT
treatment  ||| S:254 E:264 ||| NN
of  ||| S:264 E:267 ||| IN
various  ||| S:267 E:275 ||| JJ
tumor  ||| S:275 E:281 ||| NN
types ||| S:281 E:286 ||| NNS
.  ||| S:286 E:288 ||| .
Among  ||| S:288 E:294 ||| IN
the  ||| S:294 E:298 ||| DT
most  ||| S:298 E:303 ||| RBS
promising  ||| S:303 E:313 ||| JJ
cancer  ||| S:313 E:320 ||| NN
gene  ||| S:320 E:325 ||| NN
therapy  ||| S:325 E:333 ||| NN
approaches  ||| S:333 E:344 ||| NNS
are  ||| S:344 E:348 ||| VBP
oncolytic  ||| S:348 E:358 ||| JJ
adenoviruses ||| S:358 E:370 ||| NN
,  ||| S:370 E:372 ||| ,
which  ||| S:372 E:378 ||| WDT
are  ||| S:378 E:382 ||| VBP
able  ||| S:382 E:387 ||| JJ
to  ||| S:387 E:390 ||| TO
infect ||| S:390 E:396 ||| VB
,  ||| S:396 E:398 ||| ,
replicate  ||| S:398 E:408 ||| VBG
in  ||| S:408 E:411 ||| IN
and  ||| S:411 E:415 ||| CC
lyse  ||| S:415 E:420 ||| JJ
tumor  ||| S:420 E:426 ||| NN
cells ||| S:426 E:431 ||| NNS
.  ||| S:431 E:433 ||| .
Recent  ||| S:433 E:440 ||| JJ
data  ||| S:440 E:445 ||| NNS
from  ||| S:445 E:450 ||| IN
clinical  ||| S:450 E:459 ||| JJ
trials  ||| S:459 E:466 ||| NNS
with  ||| S:466 E:471 ||| IN
these  ||| S:471 E:477 ||| DT
vectors  ||| S:477 E:485 ||| NNS
have  ||| S:485 E:490 ||| VBP
shown  ||| S:490 E:496 ||| VBN
that  ||| S:496 E:501 ||| IN
they  ||| S:501 E:506 ||| PRP
are  ||| S:506 E:510 ||| VBP
safe ||| S:510 E:514 ||| JJ
.  ||| S:514 E:516 ||| .
However ||| S:516 E:523 ||| RB
,  ||| S:523 E:525 ||| ,
antitumor  ||| S:525 E:535 ||| JJ
efficacy  ||| S:535 E:544 ||| NN
needs  ||| S:544 E:550 ||| VBZ
to  ||| S:550 E:553 ||| TO
be  ||| S:553 E:556 ||| VB
improved  ||| S:556 E:565 ||| VBN
to  ||| S:565 E:568 ||| TO
make  ||| S:568 E:573 ||| VB
oncolytic  ||| S:573 E:583 ||| VBN
adenoviruses  ||| S:583 E:596 ||| VBG
a  ||| S:596 E:598 ||| DT
viable  ||| S:598 E:605 ||| JJ
treatment  ||| S:605 E:615 ||| NN
alternative  ||| S:615 E:627 ||| NN
for  ||| S:627 E:631 ||| IN
cancer  ||| S:631 E:638 ||| NN
patients ||| S:638 E:646 ||| NNS
.  ||| S:646 E:648 ||| .
This  ||| S:648 E:653 ||| DT
review  ||| S:653 E:660 ||| NN
focuses  ||| S:660 E:668 ||| VBZ
on  ||| S:668 E:671 ||| IN
targeting  ||| S:671 E:681 ||| VBG
strategies  ||| S:681 E:692 ||| NNS
to  ||| S:692 E:695 ||| TO
improve  ||| S:695 E:703 ||| VB
tumor  ||| S:703 E:709 ||| NN
cell  ||| S:709 E:714 ||| NN
transduction  ||| S:714 E:727 ||| NNS
and  ||| S:727 E:731 ||| CC
cancer  ||| S:731 E:738 ||| NN
cell  ||| S:738 E:743 ||| NN
selective  ||| S:743 E:753 ||| JJ
replication ||| S:753 E:764 ||| NN
.  ||| S:764 E:766 ||| .
Strategies  ||| S:766 E:777 ||| NNS
to  ||| S:777 E:780 ||| TO
improve  ||| S:780 E:788 ||| VB
antitumor  ||| S:788 E:798 ||| JJ
efficacy  ||| S:798 E:807 ||| NN
by  ||| S:807 E:810 ||| IN
arming  ||| S:810 E:817 ||| VBG
the  ||| S:817 E:821 ||| DT
virus  ||| S:821 E:827 ||| NN
with  ||| S:827 E:832 ||| IN
therapeutic  ||| S:832 E:844 ||| JJ
transgenes  ||| S:844 E:855 ||| NNS
are  ||| S:855 E:859 ||| VBP
also  ||| S:859 E:864 ||| RB
discussed ||| S:864 E:873 ||| VBN
.  ||| S:873 E:875 ||| .
Furthermore ||| S:875 E:886 ||| RB
,  ||| S:886 E:888 ||| ,
an  ||| S:888 E:891 ||| DT
overview  ||| S:891 E:900 ||| NN
of  ||| S:900 E:903 ||| IN
the  ||| S:903 E:907 ||| DT
most  ||| S:907 E:912 ||| RBS
important  ||| S:912 E:922 ||| JJ
clinical  ||| S:922 E:931 ||| JJ
approaches  ||| S:931 E:942 ||| NNS
with  ||| S:942 E:947 ||| IN
oncolytic  ||| S:947 E:957 ||| JJ
adenoviruses  ||| S:957 E:970 ||| NN
is  ||| S:970 E:973 ||| VBZ
given ||| S:973 E:978 ||| VBN
.  ||| S:978 E:980 ||| .
